NEW YORK — Actim said on Tuesday that it has received the CE mark for its Actim SARS-CoV-2 rapid antigen test.
According to the Finnish company, the test is designed to detect the nucleoprotein of SARS-CoV-2 in nasopharyngeal swab samples, providing results within 15 minutes. It is effective with different variants of the virus including those originating in the UK, India, and South Africa, and has demonstrated 98 percent sensitivity and 100 percent specificity.
The firm added that the test does not cross-react with other common viruses, including coronaviruses, such as influenza A/B, or enteroviruses.
In January, Actim received CE marking for its ELISA-based SARS-CoV-2 antibody assay.